Bentsur RON
SEC-identified person · CIK 1251213 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Nuvectis Pharma, Inc. NVCT | Director · Chairman & CEO | filed 2022 - 2026 |
| Beyond Air, Inc. XAIR | Director | filed 2017 - 2024 |
| Stemline Therapeutics INC STML | Director | filed 2013 - 2020 |
| Urogen Pharma Ltd. URGN | Director · Chief Executive Officer | filed 2019 - 2019 |
| Keryx Biopharmaceuticals INC KERX | Director · VP FIN & INVESTOR RELATIONS | filed 2006 - 2015 |
| XTL Biopharmaceuticals LTD XTLB | CEO | filed 2006 - 2007 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.